在新辅助化疗中加入围手术期杜瓦单抗可为MIBC患者带来益处

IF 81.1 1区 医学 Q1 ONCOLOGY
Diana Romero
{"title":"在新辅助化疗中加入围手术期杜瓦单抗可为MIBC患者带来益处","authors":"Diana Romero","doi":"10.1038/s41571-024-00951-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 11","pages":"766-766"},"PeriodicalIF":81.1000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-024-00951-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"21 11\",\"pages\":\"766-766\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41571-024-00951-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00951-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

符合条件的肌浸润性膀胱癌(MIBC)患者通常会在根治性膀胱切除术前接受以顺铂为基础的化疗,但约有50%的患者会在3年内复发。目前,在2024年ESMO大会上同时公布的III期NIAGARA试验的最新数据表明,在新辅助化疗中加入围手术期杜瓦鲁单抗可改善这种情况下的治疗效果。共有1063名患者被随机分配(1:1)接受新辅助吉西他滨-顺铂治疗,然后接受根治性膀胱切除术,同时接受或不接受新辅助和辅助杜瓦鲁单抗治疗(分别为杜瓦鲁单抗组和对照组)。病理完全反应(pCR)和无事件生存期(EFS)是共同主要终点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信